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Acute flaccid paralysis (AFP) surveillance is key for 
global polio eradication. It allows detecting poliovi-
rus (PV) reintroductions from endemic countries. This 
study describes AFP surveillance in Spain from 1998 
to 2015. During this time, 678 AFP cases were reported 
to the Spanish National Surveillance Network. The 
mean notification rate was 0.58 AFP cases/100,000 
population under 15 years old (range: 0.45/100,000–
0.78/100,000). Two periods (P) are described: P1 
(1998–2006) with the AFP notification rate ranging 
from 0.66/100,000 to 0.78/100,000, peaking in 2001 
(0.84/100,000); and P2 (2007–2015) when the AFP rate 
ranged from 0.43/100,000 to 0.57/100,000, with the 
lowest rate in 2009 (0.31/100,000). No poliomyelitis 
cases were caused by wild PV infections, although two 
Sabin-like PVs and one imported vaccine-derived PV-2 
were detected. Overall, 23 (3.4%) cases met the hot 
case definition. Most cases were clinically diagnosed 
with Guillain–Barré syndrome (76.9%; 504/655). The 
adequate stool collection rate ranged from 33.3% 
(7/21) to 72.5% (29/40). The annual proportion of 
AFP cases with non-polio enterovirus findings varied 
widely across the study period. AFP surveillance with 
laboratory testing for non-polio enteroviruses must 
be maintained and enhanced both to monitor polio 
eradication and to establish sensitive surveillance for 
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prompt detection of other enteroviruses causing seri-
ous symptoms.
Introduction
The 1988 Global Polio Eradication Initiative (GPEI) 
included four strategies: (i) high systematic immuni-
sation with oral polio vaccine (OPV); (ii) provision of 
supplementary vaccinations; (iii) active surveillance of 
wild poliovirus (WPV) through reporting and laboratory 
testing of all acute flaccid paralysis (AFP) cases in chil-
dren < 15 years of age; (iv) once transmission has been 
limited, development of campaigns to reach any unvac-
cinated population [1].
By 2011, four of the six World Health Organization 
(WHO) Regions had seen their last indigenous polio 
cases and were certified as polio free. But polio 
proved to be insidious and poliovirus transmission 
has persisted in countries with ineffective immunisa-
tion systems and low-performing eradication activities, 
resulting in potential risk of international spread and 
virus importations into previously polio-free countries 
[2].
Despite the dramatic decrease in worldwide polio 
cases in the last few decades, the WHO estimates 
that, from 2003 to 2014, there were 191 importation 
events into previously polio-free countries, resulting in 
3,763 reported cases of paralytic polio in 43 countries. 
A Public Health Emergency of International Concern 
was declared by the WHO in 2014 [3]. Since then the 
International Health Regulations Committee recom-
mends that countries in which WPV or vaccine-derived 
poliovirus (VDPV) transmission is occurring should 
ensure and document that residents and long-term vis-
itors (i.e. > four weeks) receive a dose of polio vaccine 
Figure 1
Cases of poliomyelitis, type of polio vaccines and vaccination coverage, Spain, 1931–2015
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prior to international travel. Restriction of international 
travel of any resident lacking documentation of appro-
priate polio vaccination should be imposed at the point 
of departure [3].
On rare occasions, vaccine-associated paralytic polio-
myelitis (VAPP) may occur up to 30 days after receiving 
an OPV dose. Sabin polioviruses can also replicate in 
immunocompromised persons (iVDPV) acquiring the 
neurovirulence and transmissibility characteristics of 
WPV and they can spread in populations with low OPV 
coverage causing circulating VDPV (cVDPV) cases and 
outbreaks [4]
In September 2015, worldwide eradication of indig-
enous WPV type-2 was declared. To stop circulation 
of VDPV type-2, live attenuated type-2 poliovirus 
was withdrawn from oral vaccines as at April 2016. 
Nevertheless outbreaks caused by cVDPVs, including 
cVDPV type-2, have continued in areas of several coun-
tries [5]. This implies that long-term use of OPV poses 
an ongoing risk and, consequently the GPEI will need 
to stop OPV vaccination in addition to certification and 
WPV containment [5].
The European Regional Commission for Poliomyelitis 
Eradication (RCC) publishes an annual report with 
the main features of national reports and conclusions 
about the polio-free status of the Region. The possi-
bility of re-entry of the virus into Europe can never be 
completely discarded primarily because of low popula-
tion immunity in some countries [6].
The National Certification Committee (NCC) for polio 
eradication was established in Spain in 1998 as a 
component of the National Plan of Actions Aimed at 
the Achievement of the Certificate of Polio Eradication 
(NPCPE) [7]. An annual update on polio eradication 
activities is prepared by the NCC and submitted to the 
RCC. The report contains a statement presenting the 
evidence-based rationale for the absence of poliovirus 
circulation in the country.
Updated versions of the NPCPE were approved in 
Spain in 2007, 2011 and 2016. Nationwide, the main 
Figure 2
Acute flaccid paralysis surveillance system in Spain, reporting information flowchart
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poliovirus eradication activities are: maintenance of 
high vaccination coverage and the strengthening of 
poliovirus surveillance, including AFP and enterovirus 
(EV) surveillance [7-9].
Since the implementation of the NPCPE and the devel-
opment of the AFP surveillance system, the sensitivity 
of the surveillance has gradually decreased in relation 
to the WHO objective of being able to detect at least 
one case of AFP per 100,000 population under 15 years 
old [9]. In Spain, OPV was replaced by inactivated polio 
vaccine (IPV) in 2004. Since 1996, national coverage 
of three doses in children’s first year of age exceeds 
95%. In 2015, national coverage was 96.4% (ranging 
between 92.8 and 100.0% according to autonomous 
regions) (Figure 1).
The objective of this study is to report and evaluate 
the results of 18 years (1998–2015) of the surveillance 
programme for AFP in Spain in terms of incidence, epi-
demiological and laboratory investigations, clinical 
diagnosis, as well as utility and quality of surveillance.
Methods
Acute flaccid paralysis surveillance system in 
Spain
In Spain, AFP surveillance is the main component of 
poliovirus surveillance, along with supplementary EV 
laboratory surveillance. Environmental surveillance is 
not established nationwide. Laboratory techniques and 
protocols that should be maintained or could be devel-
oped in the event of PV importation or an outbreak are 
assessed annually by a pilot environmental study in an 
urban area. The results are reported yearly to the RCC.
AFP surveillance is mandatory in Spain. It is con-
ducted by the Spanish Epidemiological Surveillance 
System (RENAVE) together with the AFP Surveillance 
Laboratory Network, and is coordinated by the 
National Epidemiology Centre (CNE) of the Carlos III 
Health Institute (ISCIII). The Regional Epidemiological 
Surveillance Centres (RESCs) are located in each of the 
19 autonomous territories (17 autonomous regions and 
two autonomous cities). These surveillance centres are 
Figure 3
Acute flaccid paralysis surveillance system in Spain, case reporting, investigation, classification and follow-up, Spain, 
1998–2015
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made up of local networks of public and private hos-
pitals (paediatric, neurology and infectious disease 
wards) which are directly coordinated by the person in 
charge of the RESCs (Figure 2).
Case notification as well as other relevant informa-
tion is collated centrally and subsequently fed-back 
through the system, between the different levels: local, 
regional, national and international (Figure 2).
Laboratory network
The AFP Surveillance Laboratory Network coordinated 
by the National Poliovirus Laboratory (NPL) of the ISCIII 
was set up in 1998. The NPL is part of the European 
Polio Laboratory Network and is accredited annually 
by the WHO. In Spain the number of regional labora-
tories belonging to the AFP surveillance network has 
been reduced over time, decreasing from nine in 1998 
to only three in 2015. The network laboratories per-
form virological studies of notified AFP cases in their 
region, while the national laboratory studies all AFP 
cases reported by the 16 autonomous territories with-
out regional laboratories.
The network laboratories perform virological studies 
of stool samples using cell culture techniques – fol-
lowing protocols recommended by the WHO [10,11]. 
Since 2015 a new diagnosis policy has been introduced 
in all European polio laboratories and now culture 
results must be available within 14 days after labora-
tories receive samples, instead of 28 days earlier [9]. 
Laboratory analysis consists of the evaluation of viral 
growth after two blind passages on cell lines (RD and 
L20B) sensitive to poliovirus infection (3 serotypes) 
and to most of the non-polio EV (NPEV) infections. 
Negative results refer to the absence of viral growth. 
Any positive result must be sent to the national labora-
tory immediately. The NPL is responsible for confirming 
EV detection and characterising the serotype. Any viro-
logical results will be notified to the WHO through the 
Laboratory Data Management System (LDMS) (Figure 
2).
Reporting and investigation of acute flaccid 
paralysis cases
The RESCs must notify the CNE of any AFP cases occur-
ring in the 0–14 year-old population. In the event of an 
AFP case, a preliminary reporting form with clinical and 
epidemiological information has to be completed [12]. 
A hot case is a person highly suspected for polio based 
on the clinical suspicion of poliomyelitis, and who has 
either received less than three doses of polio vaccine, 
or has recently travelled to an endemic country (having 
returned up to 35 days before the onset of paralysis) 
or belongs to a high risk group [13]. If an AFP hot case 
is reported, a set of Standard Operating Procedures 
(SOP), including priority for laboratory investigation 
and contact tracing, must be implemented [9] (Figure 
3).
Clinical specimens for virological investigation have to 
be collected. A follow-up reporting form is sent to CNE 
to determine paralysis evolution after 60 days from 
paralysis onset, and to clarify the final diagnosis of the 
case. Cases are classified as confirmed, discarded or 
compatible with polio [12,13] (Figure 3).
Zero reporting
To monitor AFP surveillance quality zero reporting 
is recommended. The collaborating hospitals in the 
region should respond to RESC enquiries through a 
contact-point among the medical staff, who acts as a 
link between clinicians and epidemiologists for surveil-
lance activities. To maintain the highest coverage, a 
number of hospitals report for each region:  Andalucía 
(n = 33); Aragón (n = 9); Asturias (n = 1); Baleares 
(n = 14); Cantabria (n = 1); Canarias (n = 4); Castilla 
La Mancha (n = 12); Castilla y León (n = 18); Cataluña 
(n = 14); Comunidad Valenciana (n = 28); Extremadura 
(n = 8); Galicia (n = 10); Madrid (n = 18); Murcia (n = 10); 
Navarra (n = 1); País Vasco (n = 6); La Rioja (n = 2); Ceuta 
(n = 1) and Melilla (n = 1).  On a monthly basis, medical 
Figure 4
Acute flaccid paralysis (AFP) hospitalisation ratea and 
AFP detection rateb per 100,000 population under 15 years 
of age, Spain, 2000c–2015
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staff are asked to report non-notified AFP cases in hos-
pitalised children. If AFP cases are not found, a zero-
reporting form should be sent to the CNE in the first 7 
days of the following month. The completeness and the 
timeliness of zero reporting are used as surveillance 
quality indicators (see Table 1 in the results’ section).
Assessing acute flaccid paralysis surveillance by 
reviewing hospital discharge registries
Retrospective searches of medical records which meet 
AFP clinical criteria help to determine a baseline bur-
den for AFP in a country. Annually, each RESC conducts 
a retrospective search at the Regional Hospitalization 
Discharge Registry. The results of these searches are 
reported to the CNE. The cause of hospitalisation is 
considered to be clinically compatible with AFP when 
the Ninth International Classification of Diseases (ICD-
9-CM) [14] codes are 357.0 and 356.9 (Guillain–Barré 
Syndrome or other peripheral neuropathy), 336.9 
(acute myelitis) or 045.0 and 045.1 (acute poliomyelitis 
caused by poliovirus or other neurotropic viruses).
Assessment of quality of acute flaccid paralysis 
surveillance performance
A set of indicators are calculated annually at national 
level and compared with WHO standards. Indicators 
evaluate the main system attributes: sensitivity, com-
pleteness and timeliness of notification, investigation 
and laboratory workup. To synthetise the quality of 
AFP surveillance WHO requests the ‘surveillance index’ 
(see Table 1 in the results’ section).
Data analysis
Individualised information regarding notified AFP cases 
between 1998 and 2015 in Spain was obtained from the 
RENAVE database. Zero-case monthly reports and data 
from hospital discharge registries between 2000 and 
2015 were obtained from the AFP surveillance system. 
To calculate the AFP notification rate, population data 
were obtained from the National Institute for Statistics.
Results
Acute flaccid paralysis detection and 
demographic variables
A total of 678 AFP cases were notified between 1998 
and 2015. The annual number of AFP cases reported 
ranged from 51 (in 2001) to 21 (in 2009) respectively. All 
of the cases were discarded for polio except two VAPPs 
(1999; 2001) and one paralysis case associated with an 
iVDPV (2005). The AFP detection rate in the population 
under 15 years decreased over the study period, from 
0.78 AFP cases/100,000 in 1998 to 0.45/100,000 in 
2015; the mean AFP detection rate was 0.58/100,000.
Two periods (P) are described regarding AFP detec-
tion. The first, P1 (1998–2006), was when the AFP rate 
ranged from 0.78/100,000 in 1998 to 0.66/100,000 in 
2006; the rate peaked in 2001 at 0.84/100,000. The 
second period, P2 (2007–2015), showed an AFP rate 
ranging from 0.57/100,000 in 2007 to 0.43/100,000 in 
2015. The lowest ever reported rate was 0.31/100,000 
in 2009 (Table 1; Figure 4).
By age group, most cases (310, 45.7%) were under 5 
years old; 29.5% (200) were between 5 and 9 years old 
and 24.8% (168) were between 10 and 14 years old; the 
youngest case was a newborn aged 16 days. Overall, a 
slightly higher proportion of male cases were reported 
(383/678, 56.4%).
Vaccination status was recorded for 659 cases (97.2%). 
Among them, 637 cases (96.7%) had received three or 
more doses of polio vaccine before being diagnosed 
with AFP; two cases (0.3%), both in the 5–9 year age 
group, were completely unvaccinated; and a further 
20 cases (3.0%) had received less than three doses, 
including 16 under-vaccinated cases older than 6 
months.
Of all AFP cases, 23 (3.4%) met hot case definition, 
including two VAPPs and another paralysis case pro-
duced by an iVDPV (Table 1). The risk factors associ-
ated were: clinical suspicion of poliomyelitis (3 cases), 
having had less than three doses of polio-vaccine (16 
cases) and being immunosuppressed (9 cases); six 
cases had more than one risk factor concurrently.
Clinical features
Key clinical signs suggestive of polio were collected. 
For cases with available information, limbs were the 
most common site of paralysis (535/610, 87.7%); 20.2% 
(130/642) had fever (≥38°C) at paralysis onset; 40.4% 
(227/562) presented rapid progression to complete 
paralysis and 8.2% (50/610) had asymmetric paralysis.
All the AFP cases were hospitalised, mainly in highly 
specialised tertiary hospitals. For 655 (96.6%) of 
them a clinical diagnosis was reached. Among them, 
Guillain–Barré syndrome (GBS), including Miller Fisher 
syndrome and other polyradiculoneuritis, was the 
most common clinical diagnosis in each year of the 
whole study period (504, 76.9%), followed by myeli-
tis (44 cases, 6.7%) and other uncommon diagnoses 
like encephalomyelitis or meningitis (23 cases, 3.5%). 
Other rare reported diagnoses were tumours or multi-
ple sclerosis.
The information on follow-up was collected in 651 
cases (96.0%), of which 179 (27.4%) presented resid-
ual paralysis after 60 days of paralysis onset.
Most cases were classified as non-polio AFP (675, 
99.0%), except three cases who occurred due to a 
Sabin-like poliovirus (PV-SL) or an iVDPV. In 1999 a 
5-month-old infant presented with rapidly evolving 
asymmetric paralysis, having received the first OPV 
dose one month before; a PV-SL3 was detected in stool 
samples. The infant recovered but residual paraly-
sis persisted. In 2001, a 7-month-old infant, having 
received the second dose of OPV 3 months before, 
presented with asymmetric paralysis with a rapid evo-
lution and PV-SL2 was identified in stool samples. 
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Concurrent severe immunosuppression was diagnosed 
and the child died.
Later, in 2005, an AFP case imported from Morocco 
and resulting from a recombinant iVDPV type 2 was 
found. The case was a 14-month-old boy with residual 
paralysis and major histocompatibility complex Class 
II immunodeficiency; he had received two OPV doses, 
the second at 6 months of age. Eight months later 
the patient developed encephalitis with clinical tetra-
parexia, at which point suspicion of polio was raised 
and diagnosis confirmed. The high level of vaccination 
coverage in Spain and the rapid tracing and monitoring 
of close contacts prevented virus spread [15].
Laboratory investigations
For 92.3% (626) of the total AFP reported cases, at least 
one stool sample was collected. Taking into account 
that several samples from the same person could be 
collected, from 1998 to 2004, 14 stool samples taken 
from AFP cases or from their contacts were positive for 
PV-SL. A PV-SL3 and a PV-SL2 were isolated from two 
VAPP cases. In addition, during 2005, an iVDPV type 2 
was detected (Table 2). Furthermore, the NPL performs 
the characterisation of all NPEVs isolated. EV species 
B were the most frequent serotypes found in the stool 
samples (30; 4.4% of AFP cases), although several 
Coxsackievirus A (from species A) were also detected. 
An EV-D68 was identified in stools from a 4 year-old 
child with severe limb paralysis in 2015 (Table 2).
Quality indicators of acute flaccid paralysis 
surveillance performance
The quality of AFP surveillance has weakened over 
the surveillance system’s lifespan. The sensitivity of 
the surveillance, the AFP detection rate, has gradually 
decreased from the WHO-stated objective of at least 
one case per 100,000 inhabitants under 15 years of age 
(Table 1; Figure 4). The completeness of zero reporting 
has always been maintained at over 80%, while the 
timeliness of zero reporting decreased from 73.8% in 
2001 to 34.2% in 2012 (Table 1). The number of hos-
pitalisations with an AFP diagnosis identified in hos-
pital discharge registry searches shows a fluctuating 
pattern. A variable gap is described between the AFP 
hospitalisation rate and the AFP detection rate across 
the study period (Figure 4).
Timeliness of investigation (i.e. the investigation rate) 
reached the 80% target every year and for most cases 
at least one faecal specimen was taken; however, the 
‘adequate stool collection rate‘ always remained under 
the expected 80%, and seemed to decrease slightly 
during the second period (2007–2015) compared with 
the first period (1998–2006). Consequently, the ‘sur-
veillance index’ experienced a decrease from 0.50 in 
1998 to 0.21 in 2015 (Table 1).
The ‘adequate laboratory results rate’ has been always 
above 80% except for 2015, when the new diagno-
sis policy began and the laboratory results had to be 
communicated sooner (14 days instead of 28 days). 
After two-year period of adaptation, laboratory capa-
bilities recovered; for 2017 the ‘adequate laboratory 
results rate’ exceeded the quality target required 
(82.4% for the first sample and 85.7% for the second 
one) [16]. During the study period, the proportion of 
AFP cases with positive NPEV findings ranged from 
17.2% in 2010 to 0% in 2009 and 2014 (Table 1).
Discussion
In Spain the last endemic case produced by a WPV 
occurred in 1988 in an under-immunised population. 
After that event Spain progressively improved the polio 
vaccination coverage (since 1996 national coverage 
of three doses exceeds 95%) allowing to reach a high 
population immunity against polio. Three additional 
imported cases associated with WPV were reported 
between 1980 and 1989. Since 2004 OPV is no longer 
administered in Spain and the last cases associated 
with PV-SL were reported in 1999 and 2001 [8,17-19]. 
The European Regional Certification Commission for 
Poliomyelitis Eradication classifies Spain as at low risk 
of WPV transmission. The maintenance of high polio 
vaccination coverage minimises the risk of spread in 
case of importation, and a good-quality surveillance 
system ensures the timely poliovirus detection [6].
The quality of AFP surveillance decreased with time, 
particularly after the OPV to IPV switch, reflecting the 
loss of awareness about polio, when finding cases of 
paralysis produced by WPV or associated to vaccine 
virus are very unlikely.
During the studied period, the number of AFP cases 
reported underwent similar fluctuations to the rate of 
children hospitalised with a clinical compatible AFP 
diagnosis; the fact that the hospitalisations and notifi-
cations follow the same pattern, indicates that the sur-
veillance is working relatively well despite it detecting 
less than one case of AFP per 100,000.
In our experience, the WHO’s expected rate of at least 
one case of AFP per 100,000 population under 15 years 
of age could be overestimating the real rate of this syn-
drome among children in a country like Spain.
Although active feedback has been proven not to 
increase the proportion of reported and virologi-
cally investigated patients [20], in our experience 
zero reporting acts as a monthly reminder maintain-
ing awareness about polio among clinicians who tend 
to believe it is a long-disappeared disease. It also 
ensures that the entire country takes part in the sur-
veillance and the whole population is represented. In 
Spain, zero cases are reported, but the delay in notifi-
cation is increasingly evident.
About half of reported AFP cases are notified more 
than a week after paralysis onset. Low concern levels 
regarding polio and the delay in consulting for symp-
toms of insidious onset, such as some type of paralysis, 
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are the main causes of this reporting delay and may 
minimise the chance to implement control measures 
and/or appropriate sample collection. This is reflected 
by the ‘adequate stool collection rate’, which did not 
reach the expected 80% over the study period and the 
decrease of the ‘surveillance index’ during that time. 
Nevertheless, the investigation rate every year reaches 
the 80% target, showing that once a case enters the 
system, the investigation is conducted promptly.
In addition to discarding poliovirus infection, AFP lab-
oratory diagnosis can lead to identifying other EVs in 
patients’ stool samples. In fact, the proportion of AFP 
cases with positive NPEV findings is used as an indica-
tor for the quality of the laboratory’s EV typing.
The most frequent EVs identified in the samples from 
AFP cases across the study period were EVs from spe-
cies B (echovirus 3, echovirus 7 and echovirus 30); 
similar results were found in laboratory EV surveillance 
[17]. A systematic review about EV detections in cases 
with AFP showed that in surveillance studies, EVs from 
species B were among the most frequently detected 
[21].
The recent increase in the detection of EVs associated 
with severe neurological symptoms in children across 
Europe [22,23] has also been identified in Spain. Of 
particular concern was a an EV-A71 outbreak notified in 
2016 with many severe encephalitis cases in paediatric 
patients [24,25].
The first case of paediatric neurological disease asso-
ciated to EV-D68 infection in Spain was reported to 
the national AFP surveillance system late in 2015 [16]. 
During 2016, two additional AFP cases associated with 
EV-D68 [26] and 12 AFP cases associated with EV-A71 
were reported highlighting the importance of maintain-
ing AFP surveillance to detect concerning signals of 
unexpected EV circulation in a country [16]. Any sur-
veillance system devoted to monitoring the spread of 
EVs should take advantage of existing networks, such 
as AFP surveillance systems, non-polio EV laboratory 
networks or viral meningitis surveillance [22,27,28].
In a polio-free IPV-user country, poliomyelitis can 
arise and spread to contacts who are not properly vac-
cinated. Movements of people from areas still using 
OPV, under-vaccinated population groups, foreign-born 
children coming from endemic countries or hard-to-
reach communities can lead to the identification of AFP 
hot cases, and will trigger the Standard Operational 
Procedure until the case can be discarded [9]. The aim 
of the response plan is to implement activities aimed 
at interrupting any poliovirus transmission within 120 
days of confirmation. The response activities will be 
promptly implemented when a suspected case of polio 
or priority AFP case is reported, or when a poliovirus is 
identified by the EV surveillance or by the environmen-
tal surveillance system [9].
Re-emergence still may arise from prolonged asympto-
matic excretion of poliovirus by hospitalised primary 
immune deficient (PID) patients, through repeated 
exposure of close contacts. PID patients with a recent 
OPV vaccination should be identified and screened for 
any poliovirus excretions [29].
In 2017 no WPV transmission in the WHO European 
Region occurred [6]. One of the milestones achieved in 
2016 was the successful switch from trivalent to biva-
lent polio vaccine by all countries in the Region that 
still used OPV [30]. Cessation of the use of OPV is nec-
essary to eliminate the low long-term risks of VDPVs 
associated with its use. Countries with IPV in their 
vaccination schedule commonly share borders with 
OPV-user countries, and residents may travel back and 
forth, increasing the risk of VDPVs’ circulation.
The quality of AFP surveillance in the WHO European 
Region as a whole has not declined in recent years, 
but there are indications that vaccine coverage is in 
decline in a small number of countries, which is of con-
cern. In particular, Bosnia and Herzegovina, Romania 
and Ukraine were considered to be at high risk of a sus-
tained polio outbreak due to suboptimal performance 
of poliovirus surveillance and the low population 
immunity [6]. A further 25 countries have been consid-
ered as having an intermediate risk and an additional 
24 as having a low risk of sustained transmission in the 
event of WPV importation or emergence of VDPV [6].
Surveillance of AFP is considered as a milestone and 
the most efficient form of surveillance in the last 
phase of polio eradication. Maintaining clinical surveil-
lance of poliomyelitis in a polio-free territory is hard. 
Poliomyelitis is among 67 other diseases under manda-
tory notification to the Spanish National Surveillance 
System. Reviewing the history of AFP surveillance in 
Spain between 1998 and 2015 brings up the need for 
awareness by all healthcare professionals involved: 
medical staff in charge of paediatrics, child neurology 
or paediatric intensive care units and the personnel 
from the laboratories involved in diagnosis of these 
patients’ clinical samples.
AFP surveillance along with non-polio EV laboratory 
surveillance must be maintained and enhanced both to 
help polio eradication and to establish a sensitive sur-
veillance for prompt detection of emergent and unex-
pected circulation of other EVs.
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